Last reviewed · How we verify
Fentanyl 400 µg sublingual spray
At a glance
| Generic name | Fentanyl 400 µg sublingual spray |
|---|---|
| Sponsor | INSYS Therapeutics Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Fentanyl Sublingual Spray for the Treatment of Acute Procedure-related Pain in a Monitored Setting (PHASE3)
- Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute Pain (PHASE2)
- Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain (PHASE3)
- Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain (PHASE3)
- Pharmacokinetic Study of Fentanyl 400 µg Sublingual Spray, Actiq® 400 µg Transmucosally, and Fentanyl Citrate Injection 100 µg Intravenously (iv) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fentanyl 400 µg sublingual spray CI brief — competitive landscape report
- Fentanyl 400 µg sublingual spray updates RSS · CI watch RSS
- INSYS Therapeutics Inc portfolio CI